Story perspectives
FDA Approves Atsena's Continuous Trial for XLRS Treatment
7/12/2025
29 5
1 of 1
Story summary
- The FDA has given the green light to Atsena Therapeutics, expanding their LIGHTHOUSE study of ATSN-201 into a groundbreaking continuous trial for X-linked retinoschisis (XLRS). This crucial step paves the way for a biologics license application anticipated in early 2028, potentially bringing the first-ever treatment to patients longing for hope.
